Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimlanod in healthy Japanese and Non-Asian participants
NCT02932969Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cimlanod in heart failure (HF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability at 11 days. Started Oct 2016; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02932969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932969.